Abstract
The application of flowcytometry in the study of basophil activation for the diagnosis of allergic diseases has given interesting results in recent years. The quantification of basophil activation by flowcytometry has been proven to be a useful tool for the assessment of the immediate-type response to allergens mediated by IgE or by other mechanisms in drug allergic patients. Up to now, most basophil activation test studies reported in the literature have used CD69 or CD203c as markers to quantify basophil activation after antigen-specific stimulation. Some technical variations such as the use of whole blood or isolated leukocytes, the addition of IL-3, the conditions of storage of the blood sample, the time of incubation with allergens and their concentration can affect the results of the basophil activation tests. The basophil activation test is more sensitive and specific than other in vitro diagnostic techniques in drug allergy. In various studies, its sensitivity in allergy to muscle relaxant drugs ranges between 36 and 97.7%, with a specificity around 95%. For betalactam antibiotics, basophil activation test sensitivity is 50% and its specificity 90%. For NSAIDs, sensitivity varies between 66% and 75%; specificity is about 93%. Basophil activation test reproduces in vitro hypersensitivity mechanisms involved in immediate-type allergic reactions, allows the diagnosis of allergic and pseudo-allergic reactions particularly for drugs, which are often not detectable by serological techniques, such as determination of specific IgE.
Keywords: Drug allergy diagnosis, cellular tests, basophil activation test, CD63, sulphidoleukotrienes, betalactam allergy, NSAID hypersensitivity
Current Pharmaceutical Design
Title: Cellular Tests in the Diagnosis of Drug Hypersensitivity
Volume: 14 Issue: 27
Author(s): Maria L. Sanz, Pedro M. Gamboa and A. L. De Weck
Affiliation:
Keywords: Drug allergy diagnosis, cellular tests, basophil activation test, CD63, sulphidoleukotrienes, betalactam allergy, NSAID hypersensitivity
Abstract: The application of flowcytometry in the study of basophil activation for the diagnosis of allergic diseases has given interesting results in recent years. The quantification of basophil activation by flowcytometry has been proven to be a useful tool for the assessment of the immediate-type response to allergens mediated by IgE or by other mechanisms in drug allergic patients. Up to now, most basophil activation test studies reported in the literature have used CD69 or CD203c as markers to quantify basophil activation after antigen-specific stimulation. Some technical variations such as the use of whole blood or isolated leukocytes, the addition of IL-3, the conditions of storage of the blood sample, the time of incubation with allergens and their concentration can affect the results of the basophil activation tests. The basophil activation test is more sensitive and specific than other in vitro diagnostic techniques in drug allergy. In various studies, its sensitivity in allergy to muscle relaxant drugs ranges between 36 and 97.7%, with a specificity around 95%. For betalactam antibiotics, basophil activation test sensitivity is 50% and its specificity 90%. For NSAIDs, sensitivity varies between 66% and 75%; specificity is about 93%. Basophil activation test reproduces in vitro hypersensitivity mechanisms involved in immediate-type allergic reactions, allows the diagnosis of allergic and pseudo-allergic reactions particularly for drugs, which are often not detectable by serological techniques, such as determination of specific IgE.
Export Options
About this article
Cite this article as:
Sanz L. Maria, Gamboa M. Pedro and De Weck L. A., Cellular Tests in the Diagnosis of Drug Hypersensitivity, Current Pharmaceutical Design 2008; 14 (27) . https://dx.doi.org/10.2174/138161208786369722
DOI https://dx.doi.org/10.2174/138161208786369722 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Adipose Stem Cells and Skin Repair
Current Stem Cell Research & Therapy Cardiovascular Alterations After Spinal Cord Injury: An Overview
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Modulation of Interaction Between Virus and Eukaryotic Host by Exposure to S. aureus Bacterial Soluble Fractions
Current Organic Chemistry Synergism Effects of Ursolic Acid Supplementation on the Levels of Irisin, C-reactive Protein, IL-6, and TNF-α During High-intensity Resistance Training in Low Activity Men
Cardiovascular & Hematological Disorders-Drug Targets Nanomedicine for Intranasal Delivery to Improve Brain Uptake
Current Drug Delivery Use of Amino Acids as Counterions Improves the Solubility of the BCS II Model Drug, Indomethacin
Current Drug Delivery Nanostructured Modulators of Neuroglia
Current Pharmaceutical Design The Pharmacogenomics of Asthma Beyond its Endotypes
Current Drug Metabolism Headache in Multiple Sclerosis - Pharmacological Aspects
Current Pharmaceutical Design Expression and Characterization of a Variant of TACI (CRD2-shortTACIFc) in Pichia pastoris
Protein & Peptide Letters Extracellular Superoxide and the Growth of Pancreatic Carcinoma
Current Cancer Therapy Reviews Endothelial Remodelling and Intracellular Calcium Machinery
Current Molecular Medicine Blood Derivates in Ocular Surface Regeneration
Recent Patents on Regenerative Medicine Diagnostic Role of Survivin in Rheumatoid Arthritis: A Systematic Review
Current Rheumatology Reviews Involvement of Breast Cancer-Associated Fibroblasts in Tumor Development, Therapy Resistance and Evaluation of Potential Therapeutic Strategies
Current Medicinal Chemistry Tissue Injury and Related Mediators of Pain Exacerbation
Current Neuropharmacology Molecular Docking for Prediction and Interpretation of Adverse Drug Reactions
Combinatorial Chemistry & High Throughput Screening Subcellular Trafficking in Rhabdovirus Infection and Immune Evasion: A Novel Target for Therapeutics
Infectious Disorders - Drug Targets Potential Applications of Bacterial Cellulose in Environmental and Pharmaceutical Sectors
Current Pharmaceutical Design Short-Term Ultramicronized Palmitoylethanolamide Therapy in Patients with Myasthenia Gravis: a Pilot Study to Possible Future Implications of Treatment
CNS & Neurological Disorders - Drug Targets